ATRI Overview

Atrion Corporation (Atrion) is engaged in the development and manufacture of products for medical applications. The Company's medical products primarily serve the fluid delivery, cardiovascular and ophthalmology markets. It has developed a variety of valves designed to fill, hold and release controlled amounts of fluids or gasses on demand for use in various intubation, intravenous, catheter and other applications in fields, such as anesthesia and oncology. Atrion's cardiovascular product, Myocardial Protection System (MPS3), is a technology used in open-heart surgery that delivers fluids and medications, mixes critical drugs, and controls temperature and pressure. Its ophthalmic products include specialized medical devices that disinfect contact lenses. Atrion also manufactures a line of balloon catheters used in the treatment of nasolacrimal duct obstruction in children and adults. Its medical and non-medical products are manufactured at facilities in Florida, Alabama and Texas.

Wall Street analysts forecast ATRI stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATRI is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Atrion Corp revenue for the last quarter amounts to 48.77M USD, increased 11.26 % YoY.

Atrion Corp. EPS for the last quarter amounts to 0.23 USD, decreased -93.83 % YoY.

Atrion Corp (ATRI) has 712 emplpoyees as of February 10 2026.

Today ATRI has the market capitalization of 797.51M USD.